Fas/CD95 Ligation Induces Proliferation of Primary Fetal Astrocytes Through a Mechanism Involving Caspase 8-Mediated ERK Activation by Barca Mayo, Olga et al.
Cell Physiol Biochem 2013;32:111-120
DOI: 10.1159/000350129
Published online: July 12, 2013
© 2013 S. Karger AG, Basel
www.karger.com/cpb 111
Barca/Seoane/Señarís/Arce: Fas-Induced Astrocyte Proliferation
Cellular Physiology 
and Biochemistry
1421-9778/13/0321-0111$38.00/0
Original Paper
Accepted: May 02, 2013
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only.
Departamento de Fisioloxía,Facultade de Medicina, Universidade de Santiago de 
Compostela, 15705 Santiago de Compostela (Spain)
Tel.+34881812290, Fax +34981574145, E-Mail victor.arce@usc.es
Dr. Víctor M. Arce
Fas/CD95 Ligation Induces  
Proliferation of Primary Fetal  
Astrocytes Through a Mechanism  
Involving Caspase 8-Mediated ERK 
Activation
Olga Barcaa    Marcos Seoane    Rosa Mª Señarís    Víctor M. Arce
Departamento de Fisioloxía, Facultade de Medicina. Universidade de Santiago de Compostela, 
 15782 Santiago de Compostela, Spain; aPresent address: Neuroscience and Brain  
Technologies Department, Italian Institute of Technology, Genoa, Italy
Key Words
Astrocytes • Fas/CD95 • ERK • PI-3K • Caspase 8
Abstract
Background: Fas/CD95 is the best-studied member of the death receptor (DR) superfamily 
in the central nervous system where it can trigger cellular responses other than apoptosis, 
including the promotion of neurogenesis and neuritogenesis, stimulation of the progression 
of gliomas, and regulation of the immune response of astrocytes. Methods: We have 
investigated the role of Fas/CD95 in the regulation of the proliferation of fetal astrocytes 
in vitro, as well as the signalling pathways involved. Results: Fas/CD95 ligation stimulated 
the proliferation of primary fetal astrocytes, through a mechanism that depends on the 
activation of caspase 8 and subsequent phosphorylation of extracellular signal regulated 
kinase (ERK). Interestingly this proliferative effect is only observed with a low dose of the 
Fas/CD95 agonist. In contrast, when primary astrocytes are challenged with a high dose 
of the Fas/CD95 agonist significant cell death occurs. Conclusions: Our findings support 
that, besides its effects on cell survival, Fas/CD95 may play a complex and prominent role in 
the regulation of astrocyte proliferation during development. 
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Introduction
The surface-bound receptor Fas (CD95) is a member of the death receptor (DR) 
superfamily that was initially identified in the immune system as an apoptosis-inducing 
receptor [1, 2]. Once activated, Fas/CD95 triggers apoptosis through recruitment of the 
intracellular adaptor Fas-associated death domain (FADD, also called MORT1). FADD in turn 
recruits caspase 8 through interaction with their death effector domains (DED), leading to 
the assembly of a specific death-inducing signalling complex (DISC) at the intracellular region 
of the Fas/CD95 receptor. The recruitment of caspase 8 to the DISC results in autoproteolytic 
activation of the enzyme, which subsequently cleaves caspase 3. In some cells, caspase 8 
is inadequate to activate procaspase 3 and Fas/CD95-induced apoptosis signaling requires 
amplification through proteolytic activation of the pro-apoptotic Bcl-2 family member Bid 
(Bcl-2 inhibitory BH3-domain protein) [3-5].
As occurs with other death domain (DD)-containing receptors, Fas/CD95 has now 
emerged as an important regulator of several non-apoptotic functions in a wide range of 
cell types [6, 7]. Thus, Fas/CD95 has been shown to increase the proliferation of human 
T lymphocytes and human fibroblasts in vitro [8, 9], to accelerate liver regeneration in 
mice subjected to partial hepatectomy [10], or even to promote tumour growth [11-15]. 
Other non-apoptotic activities of Fas/CD95 ligation include generation of proinflammatory 
cytokines and chemokines in various cell types, including astrocytes [16, 17], induction of 
a hypertrophic response in cultured cardiomyocytes [18], stimulation of the maturation of 
dendritic cells [19], induction of neurogenesis [20, 21], or promotion of neurite outgrowth 
[21, 22]. Although, the physiological importance of non-apoptotic functions of Fas/CD95 
remains controversial, they have led to the general assumption of Fas/CD95 as a death 
receptor. 
Up to now, the molecular mechanisms leading to the activation of the non-apoptotic 
actions of Fas/CD95 have not been completely elucidated. However, it is widely accepted 
that the essential components of the apoptotic signaling machinery may also exert a 
prominent role in the regulation of the non-apoptotic functions of Fas/CD95 [6, 23]. In this 
regard, caspase 8 has been reported to play an essential role in the hepatic regeneration 
following partial hepatectomy in mice [24] or in the stimulation of the maturation of 
cultured monocytes [25]. Similarly, blockade of the function of FADD results in defective liver 
regeneration [26] and impaired proliferation of B and T lymphocytes [27, 28].
Fas/CD95 is the best-studied DR in the central nervous system (CNS), and provides a 
good example of how divergent the DR-mediated biological effects may be. Within the CNS 
Fas/CD95 expression has been reported in both neurons and glial cells, including astrocytes 
and oligodendrocytes [revised in 16]. However, while both neurons and oligodendrocytes 
are susceptible to Fas/CD95-mediated apoptosis, astrocytes are quite resistant to Fas/CD95 
death [17, 29-34]. In addition, Fas/CD95 can trigger cellular responses other than apoptosis 
in CNS cells, including the promotion of neurogenesis and neuritogenesis [21, 22, 35, 36], the 
stimulation of the progression of gliomas [12-14] and the regulation of the immune response 
of astrocytes [37-39].
In an attempt to gain further insight in the biological functions of Fas/CD95 signalling 
in astrocytes, we investigated its role in the regulation of the proliferation of fetal astrocytes 
in vitro. Our findings demonstrate that Fas/CD95 ligation induces a proliferative response 
in primary fetal astrocytes, via activation of caspase 8 and subsequent phosphorylation 
of extracellular signal regulated kinase (ERK). Interestingly, and in keeping with previous 
reports in both B and T cells [7, 40], this proliferative response seems to be dose-dependent: 
while low doses of the Fas/CD95 agonist stimulate cell proliferation, higher doses promote 
cell death. Altogether, our findings support a prominent role for Fas/CD95 in the regulation 
of the cellular fate of astrocytes during development. 
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Materials and Methods
Cell cultures and treatments 
Primary monolayer cultures of cortical astrocytes were established from fetal (embryonic day 15, 
E15) or neonatal (postnatal day 4.5, P4.5) Sprague-Dawley rat cerebral cortices as previously described 
[41, 42]. The care and use of all experimental animals were in accordance with institutional guidelines. Cells 
were plated in Falcon polystyrene culture dishes (BD Biosciences, San Jose, CA) and grown in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS) 
(Invitrogen Corporation, Carlsbad, CA), 2 mM glutamine, 2.5 U/mL penicillin, and 2.5 µg/mL streptomycin 
(all from Sigma-Aldrich). The cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 for 
one week and thereafter cells were trypsinized and subcultured for the different experiments. Astrocytes 
were characterized in culture by immunofluorescence using a monoclonal antibody against glial fibrillary 
acidic protein (GFAP) (Dako Diagnosticos, Barcelona, Spain) [43]. Hamster anti-Fas/CD95 antibody (Jo2) 
and its isotype control (IgG2λ2) were purchased from BD Biosciences. The specific caspase 8 inhibitor 
Z-IETD-fmk was purchased from Calbiochem (San Diego, CA). The ERK inhibitor PD98059 and the selective 
phosphatidylinositol 3-kinase (PI-3K) inhibitor LY294002 were purchased from Sigma-Aldrich.
Cell proliferation assays
In order to evaluate the effect of Fas/CD95  ligation on astrocyte proliferation, 4x104 cells were seeded 
in Falcon 24-well plates, and treated with with different concentrations of the agonistic antibody (5 or 10 µg/
mL) or with the isotype antibody (IgG2λ2) for 24 h. Cell number was determined with a Neubauer counting 
chamber. To assess the level of cell proliferation, astrocytes were labelled with bromodeoxyuridine (BrdU) 
using the FITC-BrdU Flow Kit (BD Biosciences) as described in the manufacturer’s protocol. Briefly, BrdU 
was used at a final concentration of 10µM, for the last 6 h. After washing with the BD perm/wash buffer, 
cells were fixed and permeabilized with the BD cytofix/cytoperm buffer. Astrocytes were then treated with 
DNase for 1 h at 37°C and incubated with a fluoresceinated anti-BrdU antibody and with 4 µg/mL of Hoechst 
33258, for 20 min at room temperature. Cells were examined under an Olympus fluorescence microscope 
(IX70, Olympus Optical Co, Tokyo, Japan) with the appropriate filter combination and photographed at a 
40x magnification with a DP10 microscope digital camera (Olympus Optical Co). Four random fields were 
photographed for each replicate. 
Assessment of apoptosis
Apoptotic cell death was assessed by fluorescence microscopic analysis of cell DNA staining patterns 
with Hoechst 33258, as previously described [41]. Cells were incubated with 4 µg/mL of Hoechst 33258 
(Sigma-Aldrich) for 40 min at 37°C and, after washing, cell morphology was examined under an Olympus 
fluorescence microscope (IX70, Olympus Optical Co.) with the appropriate filter combination. Four random 
fields were photographed for each replicate, and cells were scored for apoptosis by their nuclear morphology 
(shrinkage, condensation, and fragmentation) and the higher intensity of blue fluorescence. 
Western blotting
For phospho-ERK and phospho-Akt determination, cells were maintained in 1% FBS for 48 h followed 
by serum starvation for 2 h. Cells were collected by centrifugation, and the pellet was then lysated by heating 
at 95°C for 5 min in 1% SDS, and immediately cooled at 4°C for 15 min with ice-cold lysis buffer (50 mM Hepes, 
pH 7.5; 150 mM NaCl; 10% Glycerol; 1% Triton X-100; 5mM EGTA; 1.5 mM MgCl2; 20 mM Na4P2O7; 20 mM 
Na3VO4; 50 µg/mL aprotinin and 4 mM phenylmethylsulfonyl fluoride). After centrifugation (15000 g, 15 
min, 4°C) to separate cellular debris, the lysates were resolved in a 12% SDS-PAGE, and electrotransferred 
onto a nitrocellulose paper (Protran; Schleicher and Schuell, Dassel, Germany). ERK phosphorylation was 
determined with a specific antibody that recognizes phospho-p44/42 (Erk1/2) (Cell Signalling Technology 
Inc, Danver, MA). Total ERK was determined for loading control (Cell Signalling Technology). For phospho-
Akt determination, membranes were probed with a commercial kit (Phosphoplus Akt Ser473 Antibody 
Kit, New England Biolabs, USA) that allows specific recognition of both non-phosphorylated and serin-
phosphorylated Akt. Immunoreactive bands were detected with a western-light chemiluminiscence 
detection system (ECL, GE Healthcare Bio-Sciences AB, Uppsala, Sweden), photographed (HyperfilmECL, GE 
Healthcare Bio-Sciences) and scanned with a GelDoc system (Bio-Rad, Hercules, CA).
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Statistical analysis 
Results are presented as the mean+standard error (SE). The effect of the different treatments was 
compared with their respective controls by using the non-parametric Mann-Whitney test. Statistical 
significance was established at p<0.05.
Results
Fas/CD95 ligation promotes proliferation in primary fetal astrocytes
Fas/CD95 engagement with the lower dose of the agonistic antibody (5 µg/mL) 
resulted in a significant increase in the cell number as compared with control cells (Fig. 1A). 
In contrast, cell number was not modified when primary astrocytes were challenged with 
a higher dose (10 µg/mL) of the anti-Fas/CD95 antibody (Fig. 1A). Cell number was also 
unaffected by challenging primary astrocytes with the isotype antibody. The lack of effect 
of the higher dose of the Fas/CD95 agonist on cell number may depend, at least in part, on 
the apoptotic response of primary astrocytes (Fig. 1B). A significant increase in the number 
of apoptotic cells was observed when astrocytes were treated with the higher dose of the 
agonist. In contrast, apoptotic cell death was not observed when primary astrocytes were 
challenged with the lower dose of the Fas/CD95 agonist (Fig. 1B). To gain further insight 
into the mechanisms that may account for the observed increase in cell number, primary 
astrocytes were treated with 5 µg/mL of anti-Fas/CD95 antibodies in the presence of BrdU. 
As expected, the raise in astrocyte number appears to be secondary to a stimulation of cell 
proliferation as demonstrated by the increased BrdU uptake (Fig. 1B and 1C).
Fig. 1. Fas/CD95 ligation promotes proliferation in primary fetal astrocytes. A. Fas/CD95 engagement with 
the lower dose of the agonistic antibody (5 µg/mL) results in a significant increase in the cell number as 
compared with control cells. The dashed line indicates the cell counts at time 0. Each bar represents the 
mean + S.E.M. of three independent experiments in triplicate. *=p<0.05 vs. control. B. A significant increase 
in the number of apoptotic cells is observed when astrocytes are treated with the higher dose of the agonist 
(10 µg/mL). Each bar represents the mean + S.E.M. of three independent experiments in triplicate. *=p<0.05 
vs. control. C. Treatment of primary astrocytes with 5 µg/mL of anti-Fas/CD95 antibodies increases BrdU 
uptake. Each bar represents the mean + S.E.M. of three independent experiments in triplicate. * = p<0.05 vs. 
control. D. Representative images of the results shown in panel C.
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ERK activation is necessary for Fas/CD95-induced proliferation in primary fetal astrocytes
To gain further insight in the molecular mechanisms responsible for the Fas/CD95-
induced astrocyte proliferation, we investigated the involvement of the ERK and PI-3K/Akt 
pathways. Blockade of ERK phosphorylation with the specific MEK-1 inhibitor PD98059 
resulted in a significant reduction in Fas/CD95-induced proliferation, without affecting 
cell survival (Fig. 2A and 2B). Furthermore, Fas/CD95 engagement clearly stimulated the 
phosphorylation of ERK in primary astrocytes, an effect that was completely abolished by 
PD98059 (Fig. 2C). Similarly, blockade of the PI-3K pathway also resulted in a decrease in 
Fas/CD95-induced proliferation, without affecting cell survival (Fig. 2A and 2B). However, 
Fig. 2. ERK activation is necessary for Fas/CD95-induced astrocyte proliferation in primary fetal astrocytes. 
A. Blockade of either ERK or Akt phosphorylation with specific inhibitors results in a significant reduction 
in Fas/CD95-induced proliferation. The dashed line indicates the cell counts at time 0. Each bar represents 
the mean + S.E.M. of three independent experiments in triplicate. *=p<0.05 vs. control; ◊=p<0.05 vs. anti-
Fas/CD95. B. Blockade of either ERK or Akt phosphorylation with specific inhibitors does not affect cell 
survival. Each bar represents the mean + S.E.M. of three independent experiments in triplicate. C. Fas/CD95 
engagement stimulates the phosphorylation of ERK in primary fetal astrocites, an effect that is completely 
abolished by PD98059.  D. Akt phosphorylation is unchanged after Fas/CD95 treatment in primary fetal 
astrocites.
Fig. 3. ERK phosphorylation depends on caspase 
8 activation in primary fetal astrocytes. A. Cell 
proliferation induced by Fas/CD95 ligation is 
completely abrogated when cells are treated in the 
presence of an irreversible inhibitor of caspase 8. 
The dashed line indicates the cell counts at time 
0. Each bar represents the mean + S.E.M. of three 
independent experiments in triplicate. *=p<0.05 
vs. control; ◊=p<0.05 vs. anti-Fas/CD95. B and C. 
Inhibition of caspase 8 decreases the amount of 
phosphorylated ERK detected after Fas/CD95 
activation without affecting phospho-Akt levels. 
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and in contrast with the effect of Fas/CD95 engagement on ERK phosphorylation, we were 
unable to find any consistent effect of Fas/CD95 ligation on Akt phosphorylation (Fig. 2D). 
ERK phosphorylation depends on caspase 8 activation in primary fetal astrocytes
In order to investigate the involvement of caspase-8 activation in Fas/CD95-induced 
proliferation, we treated the cells in the presence of an irreversible inhibitor of caspase 8. As 
Fig. 3A shows, the cell proliferation induced by Fas/CD95 ligation was completely abrogated 
under these experimental conditions, thus confirming that activation of caspase 8 is involved 
in Fas/CD95-induced proliferation. Interestingly, inhibition of caspase 8 also resulted in a 
decrease in the amount of phosphorylated ERK detected after Fas/CD95 activation (Fig. 3B), 
thus suggesting that ERK phosphorylation also depends on caspase 8 activity. In contrast, 
phospho-Akt levels were not modified by z-IETD-FMK treatment (Fig. 3C). 
Fas/CD95 ligation fails to promote cell proliferation in primary neonatal astrocytes
The involvement of caspase 8 in Fas/CD95-induced proliferation was further investigated 
by treating rat neonatal astrocytes with Fas/CD95 agonist. As previously reported by our 
group [34], caspase 8 gene is inactivated in neonatal astrocytes and, therefore, we took 
advantage of this condition to confirm the involvement of caspase 8 in Fas/CD95-induced 
proliferation. In keeping with our hypothesis, treatment of neonatal astrocytes with activating 
anti-Fas/CD95 antibodies was unable to promote cell proliferation. Only a slight decrease in 
cell number was observed, though it did not reach statistical significance (Fig. 4B). Also in 
keeping with the results obtained when caspase 8 activity was inhibited in fetal astrocytes, 
Fas/CD95 ligation was unable to induce ERK phosphorylation in neonatal astrocytes (Fig. 
4C).
Fig. 4. Fas/CD95 ligation fails to promote cell proliferation in primary neonatal astrocytes. A. Neonatal 
astrocytes are resistant to Fas/CD95-driven apoptosis. Each bar represents the mean + S.E.M. of three 
independent experiments in triplicate. B. Treatment of neonatal astrocytes with activating anti-Fas/CD95 
antibodies is unable to promote cell proliferation. The dashed line indicates the cell counts at time 0. Each 
bar represents the mean + S.E.M. of three independent experiments in triplicate. C. Fas/CD95 ligation is 
unable to induce ERK phosphorylation in neonatal astrocytes.
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Discussion
Fas/CD95 ligation promotes proliferation in primary fetal astrocytes
Despite the expression of Fas/CD95 in astrocytes is well documented, its physiological 
role still remains to be elucidated. As a member of the DR family, Fas/CD95 has been 
reported to promote apoptosis in primary astrocytes [17, 34]. However, primary astrocytes 
are generally resistant to Fas/CD95 killing, at least under basal conditions [34, 37, 44, 45]; 
and resistance to Fas/CD95 killing has been even reported in glioma cells [14, 44]. Although 
the reasons for this resistance are not completely understood, we have recently proposed 
that silencing of caspase-8 gene may be a key factor controlling the outcome of astrocytes 
upon Fas/CD95 engagement [34]. However, other mechanisms such as the expression 
levels of Fas/CD95, the presence of the Fas-associated protein phosphatase-1 (FAP-1), or 
the activation of cellular caspase 8 (FLICE)-like inhibitory protein (c-FLIP), may also confer 
astrocyte resistance to Fas/CD95-mediated cell death [45].
As occurs in other cell types, Fas/CD95 can also transduce non-apoptotic signals in 
primary astrocytes [37, 39, 46]. In keeping with this, our findings demonstrate that Fas/
CD95 ligation can induce a proliferative response in primary fetal astrocytes, but not in 
primary neonatal astrocytes, thus supporting a possible role for Fas/CD95 in the regulation 
of astrocyte proliferation during development. Remarkably, this proliferative response 
appears to be concentration-dependent, since it could be only observed when fetal 
astrocytes were challenged with the lower dose of the agonist. In contrast, stimulation with 
high concentrations of anti-Fas/CD95 antibodies resulted in a different scenario in which 
primary astrocytes underwent apoptosis. Interestingly, a similar dual effect has been also 
reported in both T and B lymphocytes [7, 40]. In those cells, low doses of Fas/CD95 agonists 
dramatically increase cell proliferation and activation, while high doses of the agonist may 
induce cell death [7, 40]. Furthermore, a bimodal effect on astrocyte proliferation/death has 
been also recently reported for interferon β [47] thus further illustrating the complexity of 
the mechanisms involved in the regulation of astrocyte fate during development. 
Caspase 8 activation is necessary for Fas/CD95-induced astrocyte proliferation
To the present, little is known about the molecular mechanisms involved in the control 
of Fas/CD95-induced proliferation. However, it is now widely accepted that the essential 
components of the pro-death activity are also critically involved in its non-apoptotic 
consequences. This is the case of caspase 8, the primary caspase that is recruited to the DISC 
and, consequently, the most apical component of the Fas/CD95 death signaling pathway [3, 
7]. It has been reported that recruitment and activation of caspase 8 may be also necessary 
for the non-apoptotic functions of Fas/CD95 and, in this regard, caspase 8 is required for 
cytokine-induced proliferation of hemopoietic progenitor cells and T cells, and it is also 
necessary for cytokine-induced monocyte differentiation [25, 48, 49]. In addition, capase 
8 positively controls proliferation and cell-cycle progression in primary hepatocytes [50]. 
The results presented here demonstrate the importance of caspase 8 in the control of the 
proliferation of fetal astrocyts since (i) Fas/CD95-induced proliferation of fetal astrocytes is 
counteracted by inhibition of caspase 8 activity, and (ii) Fas/CD95-induced proliferation is 
absent in neonatal astrocytes, in which, allegedly caspase 8 gene is inactivated [34]. 
It is presently unclear whether these proliferative effects of caspase 8 require the 
preservation of its enzymatic activity. However, it is important to indicate that enzymatic 
inhibition of caspase 8 impairs the Fas/CD95-induced proliferation in T cells [48], myeloid 
progenitors [49] or primary fetal astrocytes (the present study). However, we cannot rule 
out that some other functions of caspase 8, or even caspase 8 independent mechanisms [40] 
may be also involved in the proliferative effects of Fas/CD95.
Caspase 8-mediated ERK activation is involved in Fas/CD95-induced astrocyte proliferation
To further establish the functional relevance of Fas/CD95-driven proliferation, we 
analyzed some of the signaling pathways that may be involved in this response. The 
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importance of ERK phosphorylation in transducing the non-apoptotic functions of Fas/
CD95 has been previously demonstrated in different cell types [13, 21, 22, 40]. Remarkably, 
the consequences of Fas/CD95-induced ERK activation include the promotion of tumor 
progression of Fas/CD95 apoptosis-resistant tumor cells [12-14] or in primary fetal 
astrocytes (the present study). Although the molecular link between Fas/CD95 engagement 
and ERK phosphorylation has not been uncovered yet, based in our findings, it appears that 
the process requires the enzymatic activity of caspase 8. In contrast with our findings, it 
has been reported that ERK activation is not blocked in a B lymphoblastoid cell line by the 
addition of the pan-caspase inhibitor Z-VAD-fmk [40]. Although we do not presently know 
the reasons for these discrepancies, we cannot rule out the existence of differences in the 
caspase 8 activation within the DISC, or the participation of yet uncharacterized proteins. 
The PI-3K/Akt pathway is another prominent signalling mechanism involved in some 
of the non-apoptotic functions of Fas/CD95 [see 43 for review]; and PI-3K has been recently 
reported as an important mediator of Fas/CD95 effects on glioma cells [36]. Reportedly, 
Fas/CD95 stimulation induces a strong phosphorylation of the catalytic unit of PI-3K in 
both Jurkat and apoptosis-sensitive glioma cells [11]. However, despite we have found that 
blockade of PI-3K signaling reduces Fas/CD95-induced proliferation, we have been unable to 
demonstrate any effect of Fas/CD95 engagement on the activation of the PI-3K/Akt pathway. 
Interestingly, other studies have also failed in detecting increased activity of PI-3K in CD95 
apoptosis-resistant glioma cells [11, 14]. Furthermore, since activation of PI-3K by Fas/
CD95  does not requires caspase activity [14], it is tempting to speculate that the PI-3K/Akt 
pathway is not a key component of the signaling mechanisms involved in the non-apoptotic 
effects of Fas/CD95  activation. 
In summary, we have found that Fas/CD95 engagement may induce a dual effect in fetal 
astrocytes: high doses of a Fas/CD95 agonist may induce cellular apoptosis, while low doses 
promote astrocyte proliferation. The growth promoting function of Fas/CD95 appears to be 
secondary to caspase 8-mediated activation of the ERK signaling pathway. Altogether, our 
findings suggest the FasL-Fas/CD95 system may play an important role in the regulation of 
astrocyte biology during development. In contrast, the importance of the FasL-Fas/CD95 
system in postnatal astrocytes may be limited by the fact that these cells do not express 
caspase-8. 
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